Benitec Biopharma announced positive interim results from its BB-301 Phase 1b/2a clinical trial for treating Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia, showing a 100% responder rate with no serious adverse events. The company plans to finalize the pivotal study design in early 2027 and start the trial mid-year. Financially, Benitec reported a net loss of $12.9 million for Q1 2027 fiscal year, with increased R&D expenses reflecting ongoing clinical development, and holds $176 million in cash. The company also plans to shift its fiscal year-end to December 31 for reporting purposes.
Benitec Biopharma's recent financial and clinical update provides context for readers. For those tracking health-sector stocks, Pluang data shows 107 of 150 US health stocks rose while 39 fell. Notable movers include TNGX at USD 24.00 with a -3.42% change, AHCO at USD 7.68 with 100% sell order activity, and ABCL at USD 11.87 with 79% buy order activity, as of Nov 13, 2026 20:42 WIB.
The Beer Institute recognized 16 outstanding professionals with its 2026 BEST IN BREW Honors, celebrating their exceptional contributions across brewing, supply chain, and leadership roles in the U.S. beer industry. This annual award highlights the d...
REalloys Inc. reported a net loss of $30.5 million in Q3 2026 but made significant progress by signing a non-binding term sheet with the U.S. Army for a heavy rare earth processing facility at Tooele Army Depot, Utah. The company is advancing its met...
Modern Mining Technology Corp. began trading on the NYSE American after raising nearly $40 million in an IPO. The company recovers valuable metals like gold, silver, and copper from electronic waste using a proprietary process, avoiding traditional m...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
